FILE – In this Monday, July 27, 2020 file photo, a nurse prepares a syringe during a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, N.Y. With coronavirus vaccines on the horizon, when and where will most Americans get their shots? Many of the details are still being worked out, as regulators review the first vaccine candidates. A federal panel of vaccine experts is meeting this week to consider Pfizer’s vaccine, and again next week for Moderna’s. (AP Photo/Hans Pennink)
The Trump administration opted last summer not to lock in a chance to buy millions of additional doses of one of the leading coronavirus vaccine contenders. That decision could delay the delivery of a second batch of doses until manufacturer Pfizer fulfills other international contracts. The revelation was confirmed Monday by people familiar with the matter. It came a day before President Donald Trump aimed to take credit for the speedy development of forthcoming coronavirus vaccines at a White House summit Tuesday. Pfizer’s vaccine is expected to be endorsed by a panel of Food and Drug Administration advisers as soon as this week.
By ZEKE MILLER and JONATHAN LEMIRE Associated Press